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ABSTRACT
Background. The value of a preoperative lymphoscintig-
raphy in melanoma patients with clinically evident regional
lymph node metastases has not been studied. Therapeutic
lymph node dissection (TLND) is regarded as the clinical
standard, but the appropriate extent of TLND is contro-
versial in all lymphatic basins.
Patients and Methods. Of the 115 consecutive patients
with surgery on palpable lymph node metastases, 34
received a pre-operative lymphoscintigraphy. Lymphatic
drainage to a second nodal basin outside the clinically
involved basin was found in 15 cases. In 13 patients, the
ectopic tumor-draining lymph nodes were excised as in a
sentinel node biopsy. The lymph nodes from the TLND
specimens were postoperatively separated and classified as
either radioactive or non-radioactive.
Results. A total of 493 lymph nodes were examined
pathologically. The largest macrometastasis maintained the
ability to take up radiotracer in 77% of cases. Radioac-
tively labeled lymph nodes carried a higher risk of being
involved with metastasis. The proportions of tumor
involvement for radioactive and non-radioactive lymph
nodes were 44.5 and 16.9%, respectively (P=0.00002). Of
the 13 ectopic nodal basins surgically explored, six har-
bored clinically occult metastases.
Conclusion. In patients undergoing TLND for palpable
metastases, tumor-draining lymph nodes in a second,
ectopic nodal basin should be excised, because they could
be affected by occult metastasis. With respect to radioac-
tive lymph nodes situated within the nodal basin of the
macrometastasis but beyond the borders of a less-radical
lymphadenectomy, further studies are needed.
Lymph node metastasis is the most frequent form of first
recurrence in patients with cutaneous melanoma if no
lymph node surgery was performed at initial diagnosis.1
Regional metastases of melanomas most frequently involve
the cervical, axillary or inguinal lymph node basins.
Lymphatic mapping with sentinel lymphadenectomy
(SLNB) has become the standard approach in treating high-
risk melanoma patients with clinically unsuspicious
regional lymph nodes. SLNB studies have shown that
lymphatic drainage to a second or even third nodal basin is
not uncommon; this happens most frequently in patients
with melanomas originating on the trunk.2–4 Although
melanomas located on extremities usually drain to the
ipsilateral inguinal or axillary basins, additional drainage to
interval nodes, iliac, popliteal or epitrochlear SLNs may be
found.5–7 Since occult lymphatic metastases most often
occur in the primary tumor-draining lymph nodes, there is
consensus that sentinel lymph nodes (SLNs) should be
excised regardless of their anatomic location.
In patients with palpably enlarged node metastases, the
current standard procedure is therapeutic regional lymph
node dissection (TLND) of the involved nodal basin. The
value of lymphatic mapping has not yet been studied. The
experience with SLNB suggests, however, that clinically
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occult metastasis to a second nodal basin might represent a
realistic danger also for patients with enlarged nodes,
especially when the primary melanoma site is suggestive
for ambiguous lymphatic drainage.
Moreover, as with SLNB, the clinically unsuspicious but
radioactively labeled lymph nodes within a nodal basin
might carry a higher risk of metastasis, even after the for-
mation of macrometastases. If so, the anatomic location of
the radioactive nodes within a nodal basin might influence
the extent of the lymph node dissection. The high morbidity
and significant nodal basin recurrence rates following TLND
make it necessary to pursue two aims in testing lymphatic
mapping in patients with enlarged node metastases: (1) to
detect all lymph nodes at risk for metastasis and (2) to avoid
unnecessary extension of the node dissection. In the present
analysis, we focus on these questions by reviewing 34
patients treated individually who received lymphoscintig-




Between May 1998 and May 2011, 115 consecutive
patients with clinically evident regional lymph node metas-
tases from melanomas were treated at the University Medical
Center in Go¨ttingen. Of these, 25 had developed nodal
recurrence following negative SLNB. There was no history
of primary melanoma and no primary tumor could be located
in 14 additional patients. The remaining 76 patients, who are
the subject of the present study, had a known primary mel-
anoma but no previous lymphoscintigraphy. In 29 patients,
the primary melanoma was diagnosed at the same time as
palpable metastases. Nodal recurrences after primary tumor
excision were noted in 47 patients.
Magnetic resonance imaging of the head and neck were
undertaken in patients with cervical metastases. All patients
with inguinal nodal metastases received computed tomog-
raphy scans in order to detect enlarged nodes in the lesser
pelvis. The size of the lymphadenopathy was determined by
preoperative ultrasound B-scans. In the majority of cases,
fine-needle aspiration cytology was performed. In three
patients who had undergone diagnostic metastasectomy, the
size of the macrometastases was taken from the pathology
report. Patients with clinical evidence of systemic metastases
were not considered in the present study.
Lymphatic Mapping
From November 2000, 34 selected patients received
preoperative lymphoscintigraphy. In this group, two
patients were actually referred for SLNB but macrome-
tastasis [1 cm was diagnosed on preoperative ultrasound
B-scans. The remaining 32 patients had clinically palpable
disease.
Lymphatic mapping was deemed necessary: (1) if
ambiguous lymphatic drainage from the primary melanoma
site was conceivable or (2) if some kind of less radical
lymph node dissection had been planned. In such cases, we
aimed to excise all clinically unsuspicious but radioactive
lymph nodes, even if they were situated beyond the borders
of the previously designated node dissection field. All
patients gave informed consent before undergoing gamma-
probe-guided lymphadenectomy.
Patients with unknown primary melanoma sites as well
as the false-negative cases after initially negative SLNB
did not receive lymphatic mapping. Lymphatic mapping
was also not carried out for patients with clinically evident
metastases in two nodal basins, for patients with enlarged
pelvic metastases, or for patients with grossly enlarged,
fixed or matted nodes. Patients who had a primary tumor
excision requiring reconstruction of the defect using skin
flaps did not undergo lymphoscintigraphy. Patients with
previously excised in-transit metastases were also not
considered eligible for lymphatic mapping. We did include,
however, patients with synchronous, surgically amenable
in-transit disease. We also included three patients on whom
diagnostic excision of the macrometastasis had been per-
formed because we felt that bidirectional lymphatic
drainage from the primary tumor site could still be
detected.
Technically the lymphoscintigraphy did not differ from
those applied on our patients with clinically unsuspicious
lymph nodes.5,6 With a PICKER SX 100—a broad-view
gamma camera equipped with a low-energy high-resolution
collimator—preoperative dynamic lymphoscintigraphy uti-
lizing dynamic acquisition during the first 30 min and static
imaging after 1–2 h was performed on each of the patients.
Approximately 18–24 h before the operation, 100 MBq of
99mTc-human albumin (Nanocoll; Nycomed Amersham
Sorin) dissolved in a volume of 0.1–0.2 ml was injected into
the dermis surrounding the primary melanoma or the biopsy
scar. This relatively high dose was chosen to enhance the
imaging process of the afferent lymphatics or deeply situated
tumor-draining lymph nodes, e.g., iliac, subcostal or para-
sternal nodes. Static images were taken anteriorly and
laterally 30 min and 2 h after injection.
Surgical Treatment
Local excision with adequate safety margins was the
standard treatment procedure of primary melanomas. Well-
established standard surgical techniques of TLND were
considered as standard of care (modified neck dissection,
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axillary dissection including nodal levels I–III with pres-
ervation of the pectoralis minor muscle, ilioinguinal
dissection). Our surgical approaches of TLND have been
previously described.8,9 An abdominoperineal rectum
extirpation along with the enlarged paraproctic node
metastases was performed on one patient.
Less Radical Node Dissections
Generally, our approach was rather conservative in
patients with increased general morbidity, with preexisting
swellings of extremities or severe adiposity, with metas-
tasis to more than one nodal basin, or in patients with
preceding in-transit metastases. The latter group has been
shown to have high risk of nodal basin recurrence despite
thoroughly performed TLND.8 We distinguished between
two types of less radical node dissections: (1) less radical
but well-standardized dissections (selective neck dissec-
tion, dissection of axillary levels I–II only or exclusively
inguinal dissection without pelvic dissection) and (2) even
more limited, nonstandardized lymph node excision
(LLND), which sometimes seemed to be appropriate for
the reasons mentioned above. In our patients who under-
went lymphatic mapping, every less radical operation
included the removal of all radioactively labeled lymph
nodes. During gamma-guided lymph node excision, a
handheld gamma probe was used (Gamma Finder; W.O.M.
World of Medicine AG, Ludwigsstadt, Germany). At the
end of TLND, the borders of the node dissection area were
generally checked for remaining radioactivity to ensure
that all tumor-draining lymph nodes had been excised.
Ectopic Tumor-Draining Lymph Nodes
In cases displaying bidirectional lymphatic drainage, the
radioactive lymph nodes located outside the clinically
involved basin were excised in the same routine manner as
in an SLNB. When micrometastasis in an additional nodal
basin was diagnosed, no further TLND was performed.
Histological Analysis
Primary tumors were examined using routine histologi-
cal methods. The SLNs excised from an additional nodal
basin outside the clinically involved basin underwent step
sections as previously described.10 Immunohistochemical
staining was performed using the streptavidin–biotin
complex method using alkaline phosphatase as the labeling
enzyme and fast red chromogen as the substrate (detection
kit K5005; Dako, Germany). The following antibodies
were used: S-100 (clone S-100, dilution 1:3,000; Dako),
HMB-45 (clone HMB45, dilution 1:200; Dako), MART-1
(clone A 103/M2-7C10/M2-9E3, dilution 1:200; Zymed,
USA), and Pan-Melanoma Cocktail (clone HMB45þM2-
7C10þM2-9E3þT311, dilution 1:300; Biocare Medical,
USA) stained by an auto-immunostainer (Immunostar 80,
Shandon Varistain 24-4, Germany).
Immediately after the surgical procedure, the lymph
nodes were separated from the TLND specimen. Using the
gamma probe it was possible to detect low amounts of
radioactivity by touching the excised lymph nodes with the
tip of the probe. Lymph nodes were considered radioactive
whenever more than 4 counts were measured ex vivo in the
absence of any background radiation.
Depending on their size, the lymph nodes from TLND
specimens were sliced into two to four sections, each of
which was embedded separately in paraffin. From each
slice four microtome samples were produced and stained
using hematoxylin and eosin (H&E), as well as immuno-
histochemical staining with anti-protein S-100 serum,
MART-1, and anti-HMB-45.
Statistical Methods
Patient data including clinical and lymphoscintigraphic
parameters, as well as histopathological results were
entered routinely into an electronic database. For the
present analysis descriptive statistics were applied. The
chi-square test was used to compare the probabilities of
metastatic involvement for radioactive and nonradioactive
lymph nodes. The proportions of metastatic involvement of
both radioactive and nonradioactive lymph nodes were also
determined for each patient, and the means were compared
using the t-test for dependent samples. The difference in
the means was characterized with a 95 % confidence
interval. Analyses of survival and relapse rates were per-
formed using Kaplan–Meier estimates. The significance
level was set at a = 5 %.
RESULTS
Patients’ Characteristics
The characteristics of the patients displaying clinically
enlarged metastases who were included in this study are
summarized in Table 1. The majority of the patients
undergoing gamma-guided lymphadenectomy (62 %) had
a primary melanoma and clinically enlarged nodal metas-
tases at the same time, whereas the majority of the patients
without lymphatic mapping (81 %) had delayed node dis-
section of nodal recurrences. Due to this imbalance, the
patients with lymphatic mapping tended to have more
aggressive primary tumors. Furthermore, our selection
criteria imply a lower nodal tumor burden in the group with
gamma-guided surgery, although this cannot be statistically
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proven through the number of pathologically involved
lymph nodes.
In the group without lymphoscintigraphy, six patients
received some type of less radical lymphadenectomy: One
patient had selective neck dissection; two patients with
bilateral axillary metastases received axillary LLNDs
(sparing the level III nodes, the lateral nodes, and the
lymphatic on the ventral side of the major vessels); three
patients received an inguinal lymphadenectomy without
pelvic dissection.
Of the 34 patients with gamma-guided lymphadenectomy,
26 received a standard TLND (8 of them had lymphatic
drainage to ectopic SLNs). The remaining eight patients
received some form of less radical lymphadenectomy: One
patient had axillary dissection of the first two levels only; three
patients received an exclusively inguinal lymphadenectomy,
and five had nonstandardized LLNDs. Of the eight patients
with less radical procedures, seven had ectopic SLNs. Some
patients had more than one reason for restricting the proce-
dure, such as in-transit metastases, significantly increased
general morbidity, or bilateral node excision. Importantly, all
radioactive lymph nodes were excised in all less radical pro-
cedures. The percentages of patients undergoing less radical
procedures in the groups with and without lymphatic mapping
were 24 and 14 %, respectively. As a result, the mean number
of excised lymph nodes was lower in the lymphatic mapping
group (14 versus 20 nodes).
Analysis of the Lymphatic Mapping Group
The greatest diameter of the largest metastasis ranged
from 1.1 to 6.5 cm (median 3.0 cm). Lymphoscintigraphy
detected at least one radioactive node in 30 of the 34
clinically involved basins. All but one patient displayed at
least one radioactive lymph node; the average was five
radioactive nodes per patient. In the surgical specimens, the
largest macrometastasis was radioactive in 24 of the 31
cases available for analysis. The median number of excised
radioactive lymph nodes was 5 (range 0–15).
Most of the primary tumor sites were suggestive for
bivalent lymphatic drainage; 16 were situated near the
midline of the body, whereas 15 were located in a border
region between two ipsilateral nodal basins. Lymphatic
drainage to a second (ectopic) nodal basin included the axilla
(n = 8), the parasternal nodes (n = 1), the groin (n = 4), the
lesser pelvis (in the absence of drainage to the ipsilateral
groin, n = 1), and the popliteal fossa (n = 1). Of the 15
additional nodal basins detected through lymphoscintigra-
phy, 14 were surgically explored. The corresponding SLNs
were successfully excised in 13 patients (Table 2).
Pathological Findings
SLNs situated in a separate (ectopic) nodal basin were
involved with micrometastasis in six cases (four patients
with simultaneous excision of primary melanoma and
lymph node metastases and two patients with delayed
lymph node dissection for a palpable recurrence).
The metastatic disease was restricted to the radioactive
nodes in 15 of the 29 patients undergoing standardized
TLND. Patients with metastases exclusively within radio-
active nodes had a significantly lower number of lymph
node metastases as compared with patients with negative
nonradioactive nodes (2.9 ± 1.9 versus 5.0 ± 4.3 node
metastases, P = 0.03). In five patients (one of whom did
not display any radioactive nodes), the metastasis was
restricted to the nonradioactive nodes. Overall, we excised
172 radioactive lymph nodes; 71 (41.2 %) were determined
to be pathologically positive. Of the 321 nonradioactive
lymph nodes excised, 55 (17.1 %) were pathologically
positive. The proportion of tumor involvement for


















34 (81 %) 13 (39 %)
Location of
macrometastasis (N)
Neck (3) Neck (2)
Axilla (23) Axilla (19)
Groin (16) Groin (12)
Paraproctium (1)




65 (18–84) 60 (30–83) 0.99




4.65 ± 5.3 5.8 ± 4.7 0.13
Breslow, median
(min–max) (mm)
3.0 (0.5–30) 5.4 (0.65–23)












19.8 ± 20.4 14.5 ± 7.2 0.37
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radioactive and nonradioactive lymph nodes was also cal-
culated for each patient. The resulting mean probabilities
were 44.5 and 16.9 %, respectively [P = 0.00002, differ-
ence 27.6 % (95 % confidence interval 12.3–43.1 %)].
Thus, the radioactively labeled nodes carried a significantly
higher risk of being tumor-involved.
Follow-Up
Local recurrence after lymphadenectomy was defined as
any evidence of recurrent disease within the surgical basin
harboring the macrometastasis, including relapses after
generalized metastasis. The recurrence and survival rates
for the patients with and without lymphoscintigraphy are
shown in Fig. 1. The two groups are not directly compa-
rable because our selection criteria appeared to favor a
higher nodal tumor burden in the control group. However,
a local recurrence rate of about 10 % in the lymphoscin-
tigraphy group seems to be an acceptable result for a group
with exclusively palpable nodes and a mean Breslow
thickness of 5.8 mm. Of the patients who underwent some
kind of less radical gamma-guided dissection, two recurred
within the node dissection field. One of them had initially
received excision of in-transit metastases and LLND of
cervical macrometastases. In this patient, the disease
recurred with the same metastasis pattern. The second
patient had a superficial inguinal node dissection plus
excision of contralateral pelvic SLNs. This disease recurred
within the scar of the inguinal dissection simultaneously
with hepatic metastasis. We did not observe any recur-
rences in any of the 13 ectopic basins. However, one
patient diagnosed with initial lymphatic drainage to only
one axilla showed recurrence in the contralateral axilla.
Thus, in the group with gamma-guided lymphadenectomy,
20.6 % of the patients showed metastasis to more than one
nodal basin.
In the group without lymphoscintigraphy, 9.5 % of the
patients showed metastasis to two different nodal sites: One
patient had bilateral cervical metastasis; two patients had
bilateral axillary metastases. A further patient with a primary
melanoma of the calf and enlarged inguinal and iliac metas-
tases developed an isolated recurrence in the fossa poplitea.
TABLE 2 Characteristics of the patients with lymphatic drainage to ectopic nodal basins



















Paraproctium Abdominoperineal resection Right groin SLNB Positive
2 Back midline Groin Inguinal TLND Contralat. groin SLNB Positive
3 Back midline Groin Ilioinguinal TLND Ipsilat. axilla SLNB Negative
4 Right back Axilla Axillary TLND Contralat. axilla SLNB Positive
5 Back midline Axilla Axillary LLND Contralat. axilla SLNB Positive
6 Introitus urethras Groin Inguinal TLND plus ipsilateral iliac
SLNB
Contralat. groin SLNB Negative
7 Left little toe Groin Ilioinguinal TLND Popliteal SLN Not Found
8 Back midline Axilla Axillary TLND Contralat. axilla SLNB Positive
9 Left epigastrium Axilla Axillary TLND Parasternal Not Exposed
10 Back midline Backa Excision with safety margin, ipsilat.
axillary LLND
Contralat. backb SLNB Negative
11 Right shoulder Supraclavicular
modes
Supraclavicular LLND Ipsilat. axilla SLNB Positive
12 Lumbar midline Groin Ilioinguinal TLND Contralat. groin SLNB Negative
13 Sternum midline Axilla Axillary TLND Contralat. axilla SLNB Negative
14 Umbilicus
midline
Groin Inguinal TLND Contralat. Iliac nodes SLNB Negative
15 Back midline Axilla Axillary TLNDc Contralat. axilla SLNB Negative
TLND therapeutic lymph node dissection, LLND less extended, atypical lymph node excision including macrometastasis and radioactive nodes,
contralat. contralateral, ipsilat. ipsilateral, SLNB sentinel lymph node biopsy
a 11 o’clock in the ‘‘lithotomy position’’
b Triangular intermuscular space
c Axillary dissection of levels I–II only
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DISCUSSION
We have demonstrated that the concept of an ‘‘orderly
progression’’ of melanoma nodal metastases maintains its
validity for the majority of patients with clinically enlarged
nodal metastases.11 Metastasis to lymph nodes outside a
clinically involved basin can be detected by lymphoscin-
tigraphy and gamma-probe-guided lymph node dissection.
This is an observation that has not been mentioned in any
previous studies. Another observation especially worthy of
note is that the radioactive lymph nodes within a clinically
involved nodal basin carried a significantly higher risk of
being involved with metastases.
The mean number of radioactive lymph nodes was five
per patient, which appears to be high in comparison with
SLNB. Here we confirm that a considerable proportion of
the enlarged node metastases maintain the capacity to take
up radiotracer.12 The excised macrometastases were,
however, often far less radioactive when compared with the
SLNs of patients with clinically unsuspicious nodes,
making them easy to miss by lymphoscintigraphy.
Our observations underscore the need for a more indi-
vidualized approach in lymph node surgery in patients with
enlarged regional lymph node metastases. In fact, the sur-
gical treatment of clinically enlarged node metastasis has
not changed in a noteworthy manner for many years. A
TLND is usually performed, in which the macrometastasis
and the neighboring unsuspicious lymph nodes constituting
a nodal basin or a level of a nodal basin are removed.
While less than 30 % of completion lymph node dissec-
tions are tumor-positive after excision of a micrometastasis
in a sentinel lymph node (SLN), this proportion rises to 55–
75 % following the diagnostic excision of a clinically
enlarged metastatic node.13–18 Moreover, as compared with
SLNB and completion lymph node dissection, performed at
an early stage, TLND for clinically enlarged metastases has
yielded a significantly higher number of affected lymph
nodes.19,20 In our study, the nodal disease was restricted to
the radioactive nodes in only 52 % of the patients with
radical procedures. It also has to be considered that local
failure rates after excision of palpable node metastases are
unsatisfactory.8,9,21 These observations support the present
standard of performing radical TLNDs for clinically
enlarged node metastases. Still, there are three main goals:
cure, regional tumor control, and staging. Long-term sur-
vival can be achieved in about 29–52 % (39 % in the
present study).22
One especially important problem is, however, that
radical lymph node dissection carries risks of considerable
morbidity, which may substantially affect a patient’s
quality of life. From this point of view, an ideal lym-
phadenectomy should include all metastases but only a
minimum of tumor-free lymph nodes. So far, the SLN
concept has enhanced research in this direction only in
patients with clinically occult metastases.23,24
Up until now, the appropriate extent of a TLND has
remained controversial for all lymphatic basins.25,26 For
the treatment of neck metastases, functional neck dissec-
tion or selective neck dissections are presently replacing
radical neck dissection. However, almost a quarter of head
and neck melanomas metastasize outside clinically pre-
dicted neck levels.27 In the axilla, level I, II, and III
dissection is most commonly performed, although some
include level III only when suspicious nodes are present.18
Considering the poor prognosis of patients with iliac
metastases and the increased rate of lymphedema after iliac
(a) (b)FIG. 1 Local recurrence rates
(including relapses after
generalized metastases) (a) and
survival rates (b) for patients
with clinically enlarged regional
lymph node metastases who had
either gamma-guided or
classical therapeutic lymph
node dissection (TLND). The
estimated local failure- and
survival rates for all 77 patients
with palpable metastases were
25 and 39 %, respectively
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clearance, some surgeons advise to exclusively perform a
superficial inguinal node dissection when inguinal nodes
are palpably enlarged.28,29 In some instances, an even less
radical, atypical bloc dissection may be performed in
selected patients, mostly because of significant general
morbidity. A limited bloc dissection may also be consid-
ered adequate if surgically treatable locoregional cutaneous
metastases are present. It is an unfortunate truth that the
recurrence rates of nodal basin metastases are high in such
patients despite thorough TLND.8,9 Metastasis to a second
nodal basin might be a further indication for a less radical
approach, in order to avoid increased postoperative mor-
bidity. This is the reason why we did not perform a second
TLND after the excision of ectopic SLN metastasis. For-
tunately, we did not observe recurrences in an ectopic
nodal basin.
Clearly, even radical TLND loses its efficacy if occult
nodal metastasis is present outside the node dissection field.
It therefore seems advisable to remove all radioactive nodes,
i.e., the nodes that face a higher risk of being tumor-involved.
In the present study, the overall number of excised nodes was
higher in the patients with classical TLND than in the
patients with lymphatic mapping (20 versus 14 nodes).
Nevertheless, regional control did not appear to be com-
promised after gamma-guided lymphadenectomy (Fig. 1).
The demonstration of occult, ectopic lymph node
metastases in this study is the most convincing argument in
favor of a more individual approach in lymph node surgery
of enlarged regional lymph node metastases. A consider-
able proportion of the patients suspected to have
ambiguous lymphatic drainage from their primary tumor
sites did indeed display tumor-draining lymph nodes out-
side the clinically involved nodal basin. Of the 13
additional nodal sites that were explored successfully, 6
(46 %) were involved with occult metastasis. It is note-
worthy that we found lymph node metastases outside the
clinically involved basin, both in patients with clinically
enlarged nodal metastases at initial diagnosis, as well as in
patients with nodal recurrences.
Unfortunately, for some patients, lymphatic mapping
does not seem to be an option: Grossly enlarged or matted
nodes seem to be unsuitable. Moreover, flap reconstruction
at the primary tumor site may lead to inaccurate results of
lymphoscintigraphy.30 The original lymphatic drainage
pathway from the primary tumor site can also be destroyed
following the excision of in-transit metastases or after a
false-negative SLNB. We did include, however, three
patients on whom a diagnostic excision of the macrome-
tastasis had been performed because we felt that
bidirectional lymphatic drainage from the primary tumor
site could still be detected.
A gamma-guided lymphadenectomy might be helpful to
avoid missing the radioactive lymph nodes, i.e., the nodes
with the highest risk of metastatic involvement. In patients
with selective neck dissections, superficial inguinal dis-
section, or other types of less radical lymph node excision,
radioactively labeled lymph nodes may be situated beyond
the borders of the dissection. Theoretically, such radioac-
tive nodes might be primary tumor-draining nodes but also
second-echelon nodes or nodes receiving lymph from
anastomoses formed due to metastatic blockage of the
original lymphatic drainage pathways. Further studies on
the impact of these nodes are needed. Our results clearly
indicate that lymphatic mapping should not be withheld
from patients with clinically enlarged node metastases who
may display ambiguous lymphatic drainage from their
primary tumor site. As shown in the present study, tumor-
draining lymph nodes in ectopic nodal basins can be
affected by occult metastases. Performing only a standard
TLND on the patients concerned might negatively affect
staging, local tumor control or even survival.
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